Alectinib shows benefit across genetic profiles in resected ALK-positive NSCLC
New data from the ALINA study confirm lack of influence of EML4-ALK variant on outcome in this patient population
New data from the ALINA study confirm lack of influence of EML4-ALK variant on outcome in this patient population
Studies reveal promising evidence for the more precise tailoring of immunotherapy and the role of AI in improving response evaluation
Research is moving forward to understand the value of this blood-based technology as a prognostic tool
Longer duration of efficacy reported for encorafenib plus binimetinib as a treatment for NSCLC harbouring a BRAF V600 mutation
The use of targeted agents in first and subsequent lines of therapy is improving outcomes in patients with mutated lung cancer progressing on standard chemotherapy, but a biomarker- or precision-guided approach is needed
Further studies are needed to understand the position of the fourth-generation agents NVL-520 and NVL-655 in the treatment paradigm of mutated lung cancer
Subgroup analyses from the ADRIATIC study support previous practice-changing findings
ESMO Women for Oncology Award Recipient Prof. Myung Hu Ahn discusses gender equity in lung cancer research
First recommendations are released from the ESMO/SIOG Cancer in the Elderly Working Group
In the MARIPOSA study, a significant improvement in progression-free survival was reported in a subgroup with poor prognostic factors
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.